All In Biotech

Drug Trial Radar · NCT07474961

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Dec 2036

Study completion Dec 2036

Sponsor

Lead sponsor
Anne Louise Tølbøll SørensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases. The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions. New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.

Conditions

  • Waldenstrom Macroglobulinaemia
  • Multiple Myeloma

Interventions

  • teclistamab OR talquetamab OR elranatamab OR linvoseltamabDrug

    ElasTEC: A phase 4, open-label, parallel-group, two-arm domain on the BLOOD-dose platform trial to evaluate the non-inferiority, safety, and effectiveness of reduced-frequency bispecific antibody treatments (teclistamab, talquetamab, elranatamab and linvoseltamab) compared with standard-frequency treatment in patients with relapsed/refractory multiple myeloma.

  • BTK inhibitors (ibrutinib and zanubrutinib)Drug

    BELLIS: A phase 4, open-label, parallel-group, two-arm domain to assess the effectiveness and safety of reduced-dose BTK inhibitors (ibrutinib and zanubrutinib) compared to standard-dose in male and female patients with Waldenström´s macroglobulinemia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: OS is defined as the time from randomization until the time of death due to any cause, assessed up to 5 years.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Roskilde University Hospital

    Roskilde, Denmark

  • Copenhagen University Hospital - Rigshospitalet

    Copenhagen, Greater Copenhagen Area, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.